Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Deffered Revenue (2016 - 2025)

Traws Pharma (TRAW) has disclosed Non-Current Deffered Revenue for 14 consecutive years, with $2.5 million as the latest value for Q1 2025.

  • For Q1 2025, Non-Current Deffered Revenue fell 8.3% year-over-year to $2.5 million; the TTM value through Mar 2025 reached $2.5 million, down 8.3%, while the annual FY2024 figure was $2.6 million, 8.1% down from the prior year.
  • Non-Current Deffered Revenue hit $2.5 million in Q1 2025 for Traws Pharma, down from $2.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $3.4 million in Q1 2021 and bottomed at $2.5 million in Q1 2025.
  • Average Non-Current Deffered Revenue over 5 years is $3.0 million, with a median of $3.0 million recorded in 2023.
  • Year-over-year, Non-Current Deffered Revenue fell 6.21% in 2021 and then decreased 8.3% in 2025.
  • Traws Pharma's Non-Current Deffered Revenue stood at $3.2 million in 2021, then dropped by 6.97% to $3.0 million in 2022, then dropped by 7.49% to $2.8 million in 2023, then decreased by 8.1% to $2.6 million in 2024, then dropped by 2.22% to $2.5 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $2.5 million, $2.6 million, and $2.6 million for Q1 2025, Q4 2024, and Q3 2024 respectively.